Aardvark Therapeutics, Inc. (AARD) News
Track canonical SquawkNews coverage tagged to AARD, Aardvark Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 2 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Aardvark Therapeutics Q2 EPS Beats Estimate
Aardvark Therapeutics reports Q2 EPS of $(0.66), beating the $(0.91) estimate
EARNINGS | Aug 11, 2026, 08:55 PM UTC
L
AARD Reports Q2 2026 Financial Results
Aardvark Therapeutics reports second quarter 2026 financial results and provides business updates
EARNINGS | Aug 11, 2026, 08:53 PM UTC
L
AARD - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
AARD - Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSS
EQUITY | Jun 25, 2026, 01:01 PM UTC